Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5879)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2014 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i24/7686.htm |
| Number | Citing Articles |
| 1 |
Teresa Broquetas, Montserrat Garcia-Retortillo, Juan José Hernandez, Marc Puigvehí, Nuria Cañete, Susana Coll, Beatriz Cabrero, Maria Dolors Giménez, Ricard Solà, José A. Carrión, Isabelle Chemin. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLOS ONE 2017; 12(11): e0188303 doi: 10.1371/journal.pone.0188303
|
| 2 |
Ezequiel Ridruejo. Editorial: biomarkers in HBV and prediction of treatment response. Alimentary Pharmacology & Therapeutics 2021; 53(2): 332 doi: 10.1111/apt.16171
|
| 3 |
Carla S. Coffin, Kali Zhou, Norah A. Terrault. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019; 156(2): 355 doi: 10.1053/j.gastro.2018.11.037
|
| 4 |
R. J. Wong, M. T. Nguyen, H. N. Trinh, C. Chan, A. Huynh, M. T. Ly, H. A. Nguyen, K. K. Nguyen, S. Torres, J. Yang, B. Liu, R. T. Garcia, T. Bhuket, R. Baden, B. Levitt, E. da Silveira, R. G. Gish. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community‐based real‐world study. Journal of Viral Hepatitis 2017; 24(12): 1089 doi: 10.1111/jvh.12736
|
| 5 |
Joonhong Park, Taewon Bae, Yonggon Cho, Dalsik Kim, Jaehyeon Lee. Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen. Medicina 2021; 57(12): 1307 doi: 10.3390/medicina57121307
|
| 6 |
Maryam Moini, Scott Fung. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022; 14(4): 657 doi: 10.3390/v14040657
|
| 7 |
Emilia Hadziyannis, Andreas Laras. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes 2018; 9(10): 469 doi: 10.3390/genes9100469
|
| 8 |
Rosa M. Martín Mateos, Víctor F. Moreira Vicente, Eduardo Tavío Hernández, Jose Luis Cuño Roldán, Luis Téllez Villajos, Marta Aicart Ramos, Julia Arribas Anta, Celia Zaera de la Fuente, Agustín Albillos Martínez. ¿Es posible suspender el tratamiento con antivirales orales en los pacientes con hepatitis crónica B antígeno e negativa? Experiencia y nuevas expectativas. Gastroenterología y Hepatología 2015; 38(5): 305 doi: 10.1016/j.gastrohep.2014.12.001
|
| 9 |
Guan-Huei Lee, David Hsingyu Chen, Seng-Gee Lim. Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon Therapy. Current Hepatology Reports 2016; 15(4): 230 doi: 10.1007/s11901-016-0325-7
|
| 10 |
Gian Paolo Caviglia, Yulia Troshina, Enrico Garro, Marcantonio Gesualdo, Serena Aneli, Giovanni Birolo, Fabrizia Pittaluga, Rossana Cavallo, Giorgio Maria Saracco, Alessia Ciancio. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. Journal of Clinical Medicine 2021; 10(15): 3308 doi: 10.3390/jcm10153308
|
| 11 |
Hemda Schmilovitz-Weiss, Rachel Gingold-Belfer, Alon Grossman, Nidal Issa, Doron Boltin, Yichayaou Beloosesky, Nira Morag Koren, Joseph Meyerovitch, Avraham Weiss, Mark W. Sonderup. Lowering the upper limit of serum alanine aminotransferase levels may reveal significant liver disease in the elderly. PLOS ONE 2019; 14(4): e0212737 doi: 10.1371/journal.pone.0212737
|
| 12 |
Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy. Chinese Medical Journal 2016; 129(8): 929 doi: 10.4103/0366-6999.179802
|
| 13 |
Carla Osiowy, Carla Coffin, Anton Andonov. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Current Treatment Options in Infectious Diseases 2016; 8(3): 177 doi: 10.1007/s40506-016-0080-x
|
| 14 |
Yin Wu, Chang Gao, Shaohang Cai, Muye Xia, Guichan Liao, Xiaoyong Zhang, Jie Peng. Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs. Frontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00243
|
| 15 |
Ergenekon Karagoz, Alpaslan Tanoglu. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection. Hepatitis Monthly 2017; 17(4) doi: 10.5812/hepatmon.36112
|
| 16 |
Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. Experimental and Therapeutic Medicine 2017; 13(6): 3624 doi: 10.3892/etm.2017.4422
|
| 17 |
Shirin Demma, Geoffrey Dusheiko. The current treatment situation and definitions of a cure for chronic HBV infection. Future Virology 2016; 11(1): 79 doi: 10.2217/fvl.15.93
|
| 18 |
Nadia Warner, Stephen Locarnini, Hui Xu. The role of hepatitis B surface antibodies in HBV infection, disease and clearance. Future Virology 2020; 15(5): 293 doi: 10.2217/fvl-2019-0147
|
| 19 |
Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Tsung-Hui Hu, Hwa-I Yang, Sheng-Nan Lu, Yen-Hsuan Ni, Won-Long Chuang, Chuan-Mo Lee, Jaw-Chin Wu, Pei-Jer Chen, Yun-Fan Liaw. Taiwan consensus statement on the management of chronic hepatitis B. Journal of the Formosan Medical Association 2019; 118(1): 7 doi: 10.1016/j.jfma.2018.11.008
|
| 20 |
Geoffrey Dusheiko. Current and future directions of management of hepatitis B: steps toward a cure. Future Virology 2018; 13(3): 189 doi: 10.2217/fvl-2017-0103
|
| 21 |
Na Yang, Jin Feng, Taicheng Zhou, Zhuoran Li, Zhengyu Chen, Kaihua Ming, Guangtie Liang, Xiu‐xia Lei, Bang‐Lao Xu. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients. Journal of Medical Virology 2018; 90(7): 1240 doi: 10.1002/jmv.25080
|
| 22 |
Kunal Kerkar, Manisha Tiwari, Dhermendra K. Tiwari, Savita Kerkar. Microbial Products for Health, Environment and Agriculture. Microorganisms for Sustainability 2021; 31: 183 doi: 10.1007/978-981-16-1947-2_8
|
| 23 |
Yi-Cheng Chen, Yun-Fan Liaw. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016; 17(3): 355 doi: 10.1517/14656566.2016.1118056
|
| 24 |
Cheng-Hsun Ho, Shu-Hui Chen, Hung-Wen Tsai, I-Chin Wu, Ting-Tsung Chang. Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement. Antiviral Research 2019; 163: 1 doi: 10.1016/j.antiviral.2018.12.021
|